We are tackling through multiple approaches. First, we are testing new gene delivery platforms to deliver wild-type CFTR in our CF lung models. Next, we are employing CRISPR-based gene editing tools to evaluate alternative gene-targeting approaches (ie. high jacking other chloride channels) to treat CF. Finally, our continued interest in developing better de novo human lung mimetics for better disease modeling and therapy discovery has led to multiple interdisciplinary collaborations across multiple academic research institutes and the National Research Councils.